AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31409606 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole
Number of subjects: 468
Study 30204841 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively framed side effect information
Number of subjects: 112
Study 30204841 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively framed side effect information
Number of subjects: 112
Study 30204841 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 112
Study 27838568 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial Thrust
Number of subjects: 30
Study 27838568 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk Lean
Number of subjects: 30
Study 27838568 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 30
Study 24930996 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance-based torso-weighting (BBTW)
Number of subjects: 20
Study 24930996 — intervention group
Group type: COMPARATOR
Intervention: Matched velocities for healthy controls
Number of subjects: 20
Study 23890785 — intervention group
Group type: EXPERIMENTAL
Intervention: Bard-Parker #15 scalpel blade
Number of subjects: 21
Study 23890785 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar electrocautery (blend function, 1; power, 20 Watts; frequency, 480 kHz)
Number of subjects: 21
Study 21429025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) - i.v. infusion of 3.0 µg/kg per h over 5 min followed by continuous infusion at 0.4 µg/kg per h (n = 30)
Number of subjects: 90
Study 21429025 — intervention group
Group type: COMPARATOR
Intervention: Propofol (PF) (n = 30)
Number of subjects: 90
Study 21429025 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (MDZ) (n = 30)
Number of subjects: 90
Study 19961636 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV plus ATC (ATC group)
Number of subjects: 41
Study 19961636 — intervention group
Group type: COMPARATOR
Intervention: PSV alone (PSV group)
Number of subjects: 41
Study 19961636 — intervention group
Group type: COMPARATOR
Intervention: PSV group
Number of subjects: 41
Study 19961636 — intervention group
Group type: EXPERIMENTAL
Intervention: ATC group
Number of subjects: 41
Study 19961636 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 17402650 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotics
Number of subjects: 0
Study 17402650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15253399 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg elemental iron daily
Number of subjects: 100
Study 15253399 — intervention group
Group type: COMPARATOR
Intervention: 200 mg elemental iron weekly
Number of subjects: 100
Study 11226079 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (2430 +/- 310 mL administered until the morning of the first postoperative day)
Number of subjects: 42
Study 11226079 — intervention group
Group type: COMPARATOR
Intervention: Gelatin (2830 +/- 350 mL administered until the morning of the first postoperative day)
Number of subjects: 42
Study 9722272 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable barriers (Polyglactin 910)
Number of subjects: 23
Study 9722272 — intervention group
Group type: COMPARATOR
Intervention: Non-resorbable barriers (ePTFE)
Number of subjects: 23
Study 7974672 — intervention group
Group type: EXPERIMENTAL
Intervention: Maloprim (pyrimethamine+dapsone)
Number of subjects: 172
Study 7974672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 2655967 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic study
Number of subjects: 500
Study 2655967 — intervention group
Group type: COMPARATOR
Intervention: Holter monitoring
Number of subjects: 500
Study 2655967 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (mexiletine, pirmenol, procainamide, propafenone, quinidine, sotalol)
Number of subjects: 500
Study 4609545 — intervention group
Group type: EXPERIMENTAL
Intervention: mepiprazole
Number of subjects: 19
Study 4609545 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 29970009 — intervention group
Group type: EXPERIMENTAL
Intervention: CURB‐65 severity score
Number of subjects: 0
Study 29970009 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART score
Number of subjects: 0
Study 26868469 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% amlexanox (lexanox 5% oral paste)
Number of subjects: 50
Study 26868469 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 50
Study 25796693 — intervention group
Group type: EXPERIMENTAL
Intervention: Longbishu Capsule combined with mesylate doxazosin
Number of subjects: 60
Study 25796693 — intervention group
Group type: COMPARATOR
Intervention: mesylate doxazosin plus placebo
Number of subjects: 60
Study 23078067 — intervention group
Group type: EXPERIMENTAL
Intervention: One-presentation/s 44-region protocol
Number of subjects: 63
Study 23078067 — intervention group
Group type: EXPERIMENTAL
Intervention: All four test variants
Number of subjects: 63
Study 20001867 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with paclitaxel or docetaxel
Number of subjects: 0
Study 17889983 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone gel
Number of subjects: 320
Study 17889983 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone insert
Number of subjects: 320
Study 16177944 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 0
Study 12691345 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAM program
Number of subjects: 29
Study 12691345 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TEAM program)
Number of subjects: 29
Study 12691345 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation questionnaire
Number of subjects: 29
Study 10383538 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled (INH) 20 mg sodium cromoglycate
Number of subjects: 11
Study 10383538 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled + oral charcoal (INHC) 20 mg sodium cromoglycate
Number of subjects: 11
Study 10383538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral (ORAL) 20 mg sodium cromoglycate
Number of subjects: 11
Study 10383538 — intervention group
Group type: COMPARATOR
Intervention: Oral + oral charcoal (ORALC) 20 mg sodium cromoglycate
Number of subjects: 11
Study 8983611 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (total of 20 ml, 0.25 per cent) injected into the subcutaneous periportal tissue and periportal parietal peritoneal injection of bupivacaine (total of 20 ml, 0.25 per cent)
Number of subjects: 80
Study 8983611 — intervention group
Group type: COMPARATOR
Intervention: Standard technique with bupivacaine (total of 20 ml, 0.5 per cent) injected into the subcutaneous periportal tissue
Number of subjects: 80
Study 1840158 — intervention group
Group type: EXPERIMENTAL
Intervention: ciclopiroxolamine (cic) cream
Number of subjects: 20
Study 1840158 — intervention group
Group type: COMPARATOR
Intervention: ciclopiroxolamine (cic)
Number of subjects: 20
Study 7055343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (Berotec) delivered as inhalation powder
Number of subjects: 15
Study 7055343 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol from an aerosol inhaler
Number of subjects: 15
Study 31126258 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT) alone
Number of subjects: 215
Study 31126258 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab (T)
Number of subjects: 215
Study 31126258 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab (T) plus pertuzumab (P)
Number of subjects: 215
Study 30383086 — intervention group
Group type: EXPERIMENTAL
Intervention: PREPARE plus an easy-to-read advance directive
Number of subjects: 986
Study 30383086 — intervention group
Group type: COMPARATOR
Intervention: Advance directive alone
Number of subjects: 986
Study 28506281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI), six sessions (60 minutes each), telephonically delivered
Number of subjects: 60
Study 28506281 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 60
Study 28506281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 60
Study 24038152 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-5334 300 mg QD
Number of subjects: 147
Study 24038152 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 70 mg QW
Number of subjects: 147
Study 24038152 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-5334
Number of subjects: 147
Study 23587455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib at a dose of 40 mg followed by 40 mg every 12 h for 48 h (Group P)
Number of subjects: 80
Study 23587455 — intervention group
Group type: COMPARATOR
Intervention: Saline as a control (Group C)
Number of subjects: 80
Study 23587455 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group P and Group C)
Number of subjects: 80
Study 20459801 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose continuous infusion of furosemide, titrated to urine output
Number of subjects: 216
Study 20459801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 18284632 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary recommendations
Number of subjects: 100
Study 18284632 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training classes
Number of subjects: 100
Study 18284632 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 100
Study 16629791 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt chamber treatment (active group)
Number of subjects: 32
Study 16629791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 32
Study 16629791 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 14636104 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent creatine, ribose, and glutamine supplementation
Number of subjects: 28
Study 14636104 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 28
Study 11185635 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 120 mg administered between dialyses
Number of subjects: 0
Study 11185635 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 120 mg administered during dialysis
Number of subjects: 0
Study 11185635 — intervention group
Group type: COMPARATOR
Intervention: Healthy male subjects (control group)
Number of subjects: 0
Study 8866807 — intervention group
Group type: EXPERIMENTAL
Intervention: qd SSKI (one daily dose)
Number of subjects: 57
Study 8866807 — intervention group
Group type: COMPARATOR
Intervention: tid SSKI (three daily doses)
Number of subjects: 57
Study 8499751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas hyperimmunoglobulin (Psomaglobin N) 250 mg/kg on days 3, 5, 7, 10, and 13
Number of subjects: 30
Study 8499751 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 30
Study 8499751 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups with inhalation injury
Number of subjects: 30
Study 8499751 — intervention group
Group type: COMPARATOR
Intervention: Bacteremic controls
Number of subjects: 30
Study 3565818 — intervention group
Group type: EXPERIMENTAL
Intervention: enflurane/nitrous oxide/oxygen
Number of subjects: 780
Study 3565818 — intervention group
Group type: COMPARATOR
Intervention: enflurane/air/oxygen
Number of subjects: 780
Study 3565818 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane/nitrous oxide/oxygen
Number of subjects: 780
Study 3565818 — intervention group
Group type: COMPARATOR
Intervention: isoflurane/air/oxygen
Number of subjects: 780
Study 31563889 — intervention group
Group type: EXPERIMENTAL
Intervention: First pass recanalization (FPR)
Number of subjects: 429
Study 31563889 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon guide catheter use
Number of subjects: 429
Study 31563889 — intervention group
Group type: COMPARATOR
Intervention: Multiple passes or rescue treatment
Number of subjects: 429
Study 30264120 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy with intravenous ertapenem for 3 days followed by 7 days of oral levofloxacin and metronidazole
Number of subjects: 530
Study 30264120 — intervention group
Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 530
Study 30264120 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy
Number of subjects: 530
Study 26561409 — intervention group
Group type: EXPERIMENTAL
Intervention: High eating frequency (8 eating occasions/d)
Number of subjects: 12
Study 26561409 — intervention group
Group type: COMPARATOR
Intervention: Low eating frequency (3 eating occasions/d)
Number of subjects: 12
Study 25011647 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 grams of prebiotic (inulin/oligofructose) daily for 12 weeks
Number of subjects: 30
Study 25011647 — intervention group
Group type: COMPARATOR
Intervention: 10 grams placebo (maltodextrin) daily for 12 weeks
Number of subjects: 30
Study 24154738 — intervention group
Group type: EXPERIMENTAL
Intervention: Mericitabine plus peginterferon alfa-2a/ribavirin
Number of subjects: 405
Study 24154738 — intervention group
Group type: EXPERIMENTAL
Intervention: Double mutant L159F/L320F
Number of subjects: 405
Study 22138360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented sea tangle (FST) 1.5 g/day for 4 weeks
Number of subjects: 48
Study 22138360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 20124794 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% MVIC
Number of subjects: 56
Study 20124794 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% MVIC
Number of subjects: 56
Study 20124794 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% MVIC
Number of subjects: 56
Study 20124794 — intervention group
Group type: EXPERIMENTAL
Intervention: 64.3% MVIC
Number of subjects: 56
Study 17335309 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Events Monitoring System (MEMS)
Number of subjects: 253
Study 17335309 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 253
Study 15709078 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic screening
Number of subjects: 600
Study 15709078 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal screening
Number of subjects: 600
Study 15709078 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600
Study 11889013 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic heart failure (SHF)
Number of subjects: 339
Study 11889013 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic heart failure (DHF)
Number of subjects: 339
Study 11889013 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated diastolic dysfunction (DD)
Number of subjects: 339
Study 11889013 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 339
Study 11889013 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of systolic dysfunction
Number of subjects: 339
Study 10448449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (15 mg/day)
Number of subjects: 30
Study 10448449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9038524 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild stimulant laxative (Dulcolax)
Number of subjects: 144
Study 9038524 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic laxative (Citramag)
Number of subjects: 144
Study 9038524 — intervention group
Group type: COMPARATOR
Intervention: No preparation
Number of subjects: 144
Study 1380006 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 546
Study 1380006 — intervention group
Group type: COMPARATOR
Intervention: Conventional embryo transfers
Number of subjects: 546
Study 6499715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 0
Study 6499715 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 31829232 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIDE intervention offered in addition to usual care
Number of subjects: 0
Study 31829232 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 29396845 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-choice trial with genotypes HS-20, OE, VA
Number of subjects: 32
Study 29396845 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-choice test with genotypes LG, VE, J, MG, MOP, HS-20, VA, MT
Number of subjects: 32
Study 29396845 — intervention group
Group type: EXPERIMENTAL
Intervention: No-choice oviposition test with genotypes VE, P1C, CCB, RI-919, H, J
Number of subjects: 32
Study 29396845 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypes VE and J
Number of subjects: 32
Study 29396845 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypes HS-20, OE, VA, VE, J
Number of subjects: 32
Study 27103607 — intervention group
Group type: COMPARATOR
Intervention: Biologic therapies targeting immunoglobulin E (IgE) and interleukin (IL)-5 pathways in CRSwNP patients.
Number of subjects: 0
Study 27103607 — intervention group
Group type: COMPARATOR
Intervention: Biologic therapies targeting the IL-4/IL-13 pathway and other type 2 inflammatory pathways in CRSwNP patients.
Number of subjects: 0
Study 24292155 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser plus Er:YAG micropeel (combined therapy)
Number of subjects: 15
Study 24292155 — intervention group
Group type: COMPARATOR
Intervention: Q-switched Nd:YAG laser (QSNY) alone
Number of subjects: 15
Study 21442171 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week supervised training programme consisting of 3 weekly sessions of aerobic, strengthening and flexibility exercises
Number of subjects: 28
Study 21442171 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 28
Study 20047363 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide exposure (4 ppm)
Number of subjects: 10
Study 20047363 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 10
Study 20047363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (100-1000 pmol/min)
Number of subjects: 10
Study 20047363 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (5-20 microg/min)
Number of subjects: 10
Study 20047363 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (2-8 microg/min)
Number of subjects: 10
Study 20047363 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (10-100 microg/min)
Number of subjects: 10
Study 20047363 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function assessment
Number of subjects: 10
Study 20047363 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled nitric oxide measurement
Number of subjects: 10
Study 17410949 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride + sodium hexametaphosphate dentifrice (Crest Pro‐Health)
Number of subjects: 116
Study 17410949 — intervention group
Group type: COMPARATOR
Intervention: Positive control toothpaste (Colgate Total Plus Whitening)
Number of subjects: 116
Study 15845756 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG, 100 mg-400 mg/day, mean modal dose 240 mg)
Number of subjects: 98
Study 15845756 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (Li, 0.8 mEq/L-1.1 mEq/L, mean modal dose 750 mg)
Number of subjects: 98
Study 15845756 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 98
Study 11983755 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach worker intervention
Number of subjects: 482
Study 11983755 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mail intervention
Number of subjects: 482
Study 11983755 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 482
Study 9862288 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity strength exercise (elastic band resistance training, at least 3 times a week for 6 months)
Number of subjects: 132
Study 9862288 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control
Number of subjects: 132
Study 7622805 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 279
Study 7622805 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (NE) reuptake inhibitors
Number of subjects: 279
Study 7622805 — intervention group
Group type: COMPARATOR
Intervention: Mixed NE/serotonin reuptake inhibitors
Number of subjects: 279
Study 7622805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 1320846 — intervention group
Group type: EXPERIMENTAL
Intervention: 254-S plus VDS
Number of subjects: 136
Study 1320846 — intervention group
Group type: COMPARATOR
Intervention: CDDP plus VDS
Number of subjects: 136
Study 6418691 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture plus carbohydrates (Gp I)
Number of subjects: 14
Study 6418691 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture plus lipids and carbohydrates (Gp II)
Number of subjects: 14
Study 6418691 — intervention group
Group type: COMPARATOR
Intervention: Solid-food general hospital diet (Gp III - control)
Number of subjects: 14
Study 31606362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 79
Study 29672552 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY vaccination
Number of subjects: 100
Study 29672552 — intervention group
Group type: EXPERIMENTAL
Intervention: MenC vaccination
Number of subjects: 100
Study 29672552 — intervention group
Group type: COMPARATOR
Intervention: MenC and MenACWY vaccinations
Number of subjects: 100
Study 26091997 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed hands-on training session (Sim group)
Number of subjects: 289
Study 26091997 — intervention group
Group type: COMPARATOR
Intervention: Unstructured hands-on session (control group)
Number of subjects: 289
Study 24315521 — intervention group
Group type: EXPERIMENTAL
Intervention: Active elastic compression stockings (ECS) used for 2 years
Number of subjects: 806
Study 24315521 — intervention group
Group type: COMPARATOR
Intervention: Placebo elastic compression stockings (ECS) used for 2 years
Number of subjects: 806
Study 22257341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentaport ZX
Number of subjects: 30